Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. - Wikidata - wikimedia - TriplyDB

Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

http://www.wikidata.org/entity/Q33824220

about

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Arachidonic acid cytochrome P450 epoxygenase pathway Epoxyeicosatrienoic acids and cardioprotection: the road to translation Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism Soluble epoxide hydrolase inhibitors and heart failure Targeting epoxides for organ damage in hypertension Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling Epoxides and soluble epoxide hydrolase in cardiovascular physiology Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts.14,15-Dihydroxy-eicosa-5(Z)-enoic acid selectively inhibits 14,15-epoxyeicosatrienoic acid-induced relaxations in bovine coronary arteries.Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions CYP2J2 overexpression protects against arrhythmia susceptibility in cardiac hypertrophy 20-Iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14,15-epoxyeicosatrienoic acid receptor Differential effect of amyloid β on the cytochrome P450 epoxygenase activity in rat brain Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice Abdominal surgical incision induces remote preconditioning of trauma (RPCT) via activation of bradykinin receptors (BK2R) and the cytochrome P450 epoxygenase pathway in canine hearts.Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts.Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo Diminished acyl-CoA synthetase isoform 4 activity in INS 832/13 cells reduces cellular epoxyeicosatrienoic acid levels and results in impaired glucose-stimulated insulin secretion.11,12-Epoxyecosatrienoic acids mitigate endothelial dysfunction associated with estrogen loss and aging: Role of membrane depolarization.Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity.Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog.Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat.Soluble epoxide hydrolase: a new target for cardioprotection 20-125Iodo-14,15-epoxyeicosa-5(Z)-enoic acid: a high-affinity radioligand used to characterize the epoxyeicosatrienoic acid antagonist binding site.Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection.Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.Cytochrome P450 and ischemic heart disease: current concepts and future directions.Cytochrome P450 (CYP) epoxygenases as potential targets in the management of impaired diabetic wound healing.Epoxyeicosatrienoic acids protect cardiac cells during starvation by modulating an autophagic response.Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.Cardiotonic Pill Reduces Myocardial Ischemia-Reperfusion Injury via Increasing EET Concentrations in Rats.

P2860

Q24597172-D7843C77-278A-4746-A335-606AC01234FA Q24653023-C2C79424-CFFD-454F-9158-CB6EEC85C6DD Q28241262-75A0DDBE-5FE6-4764-BD97-5772D4A409B6 Q28245279-23EDB02B-1E59-4B10-9CEE-9776F2D48BA1 Q28383423-5B172EB6-C3EE-4013-A51D-E5524C4309EC Q28387558-320248B8-32E6-4BB8-99C2-1459B7E64342 Q28391163-31402228-E326-488D-9828-0AF448E92D2B Q28392794-3EAD97F0-E5C2-4723-AFEF-5DD1A05AEC5E Q28393594-A1F0648B-813C-4F02-ADE7-6DFB4365E9AC Q28396313-CF01C1E0-BE72-4DEE-A4CE-51BE325003B5 Q28397084-A75F3562-A8A6-46CC-9284-5A860283270C Q33665713-1B041844-94CF-4AFE-9E5D-B299635A9049 Q33917045-B4BB5021-00D1-4A38-A81F-4563C3B8269E Q34458572-BE94D20A-10CA-4C9C-B24D-B81070866034 Q34691742-52648B96-B7C3-43A2-AC99-ABB574BDDAD2 Q34983743-87D5DCB8-A254-40FB-BB62-DF3283FF4E2B Q34999553-C7AF81F6-CDDA-480C-9FAC-2DCF0E873BD1 Q35243119-33A6AE88-F14A-4ECC-B548-5337B558120D Q35640579-688499B8-D7A8-4FD9-A3D7-B57D94BC1CD7 Q35896717-FB78D574-074A-4E07-8CB9-5DCDCC143DA5 Q36312752-41AFC638-5BA6-4AC0-92FE-835E6D62428D Q36483036-35C09190-9F8B-43EC-A70F-2F0DB219FAD8 Q36642542-79A70C56-C6E6-4E44-BBE1-7285D1B1B39A Q36824230-A61AE6F2-BCC6-41C9-BA70-C63C61DCD26F Q37022931-8C1B73A3-0DC7-4A4C-AB07-9B53707982C2 Q37038903-5C1F8BC7-9057-488A-B3B2-AD596A596FAA Q37048349-781C8882-7838-4987-85FD-60B0BEE79023 Q37150118-5B10A08E-397B-42B2-B097-E0C420EEC218 Q37264451-9AC5181E-C6B1-4A31-BC21-49FCB6AD2025 Q37264470-E974DFD0-370C-41AB-8367-57656E275980 Q37414424-D98C14C9-DD56-482D-9C6E-6EF6BC88FFA5 Q37427615-25643F1A-4473-4403-9EA0-DD92E310FBAD Q37444386-C496DB69-5D1B-4938-AB77-6661FA78EC7A Q37702053-B9F3DCDB-47B3-4DDD-8F90-E488054EDC90 Q37960812-10954279-9B63-4FEE-B938-8BBDB16D7969 Q38166022-6426EA5E-0AFE-46FC-8A1A-E07C64AC85B5 Q38288640-48B2841F-1CD5-4DA4-900B-BD06A524049A Q39070894-3653CE2A-9BE9-42E2-B933-F5710C865467 Q39392465-C3E48B33-9147-4201-AD9C-53069686CB0A Q39791243-51D4DCDB-6F80-45A7-A209-1A147BB2E84B

P2860

Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

http://www.wikidata.org/entity/Q33824220

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Effects of the selective EET a ...... nous EETs in the canine heart.

@ast

Effects of the selective EET a ...... nous EETs in the canine heart.

@en

type

label

Effects of the selective EET a ...... nous EETs in the canine heart.

@ast

Effects of the selective EET a ...... nous EETs in the canine heart.

@en

prefLabel

Effects of the selective EET a ...... nous EETs in the canine heart.

@ast

Effects of the selective EET a ...... nous EETs in the canine heart.

@en

P1433

Q33824220-8A201483-3B9D-444C-90B1-2A14181905DF

P1476

Q33824220-06F256AE-80D3-4FBF-983A-B876FDFFAB89

P2093

Q33824220-39B9150F-C15C-4825-957A-A94ADF3FA61C

Q33824220-47E48628-E38E-4482-9C2B-7A170F62AC89

Q33824220-69351D90-79B3-4641-BB61-AF1CCBA1D5A5

Q33824220-879E3626-1173-48EC-8DE0-2B9963F60198

Q33824220-C14A559A-3EFF-4B19-BB8D-9EC828676633

Q33824220-FE46B9EB-9988-423F-BF4E-651D1506EB54

P2860

Q33824220-052DC5FA-C8CD-485A-A7BA-373658BC2699

Q33824220-0EE5D75A-9F3C-48C8-8EF3-35BF8C757D9B

Q33824220-17085EA8-7052-4432-B36E-38987FADB382

Q33824220-2655F6DD-275B-43B9-B5E3-CF981E46CE1A

Q33824220-291FD875-7C5A-4640-9003-C84388A4396A

Q33824220-33836D35-8084-41B6-9252-7AD5ED597046

Q33824220-3F2C5B5D-B003-4B45-9BB7-AA810798A0D5

Q33824220-3F948D5B-53E0-4E53-8E94-4E4DBA29C560

Q33824220-40839AFE-B5D9-42C8-BABF-E6068DA4E4C0

Q33824220-620E9BAF-623D-4656-8463-DCD97E818953

P304

Q33824220-46E6FC9B-45BA-427A-B9C5-40DD69B4362C

P31

Q33824220-C4B8E966-BFBB-4BAD-9A6D-E80CEA3191F6

P356

Q33824220-80F565B8-0802-4B50-B66A-2F5A18DB4388

P433

Q33824220-F749E3BB-0CE7-4F8A-8059-AF39427A18A4

P478

Q33824220-4FC24302-D9DC-4004-B41A-B342408484F8

P50

Q33824220-47058F76-DBDE-48F8-BE5C-CC5DB533A7EE

P577

Q33824220-CCA2F40E-BB7E-4E8D-9F45-9F74B18BCB70

P5875

Q33824220-60164CF4-6ECF-4ECC-98DC-7AE0D3ED9EBC

P698

Q33824220-BD8E1ACD-C3F6-4E3F-A29B-860C2A8CA7E4

P932

Q33824220-A1DA37F9-4661-4BFD-A2AD-BFFDC9A28698

P356

AJPHEART.00186.2008

P1433

American Journal of Physiology - Heart and Circulatory Physiology

P1476

Effects of the selective EET a ...... enous EETs in the canine heart

@en

P2093

Bruce D Hammock

http://www.w3.org/2001/XMLSchema#string

Garrett J Gross

http://www.w3.org/2001/XMLSchema#string

Jeannine Moore

http://www.w3.org/2001/XMLSchema#string

Kasem Nithipatikom

http://www.w3.org/2001/XMLSchema#string

Kathryn M Gauthier

http://www.w3.org/2001/XMLSchema#string

William B Campbell

http://www.w3.org/2001/XMLSchema#string

P2860

The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase

The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity

Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart

Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2

Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway

Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury

Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function

Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury

Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors.

Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.

P304

H2838-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPHEART.00186.2008

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

294

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5411598

http://www.w3.org/2001/XMLSchema#string

P698

18441205

http://www.w3.org/2001/XMLSchema#string

P932

2863006

http://www.w3.org/2001/XMLSchema#string